Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03226262 · ClinicalTrials.gov registry record

FFRangio Accuracy vs. Standard FFR

A clinical trial, sponsored by CathWorks.

Completed
Registry status
382
Enrollment target

NCT03226262: Completed study, sponsored by CathWorks.

NCT03226262 is a clinical trial that has completed, run by CathWorks. The registered enrollment target is 382 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03226262 has completed, sponsored by CathWorks.

COMPLETED
Registry status
382 participants
Enrollment target

Study Summary

This is a prospective, observational, multi-center, single-arm, clinical trial designed to assess the efficacy of FFRangio in measuring FFR obtained from angiography compared to Invasive FFR for diagnosing hemodynamically significant coronary stenosis.

Primary Outcome

Sensitivity and specificity of the dichotomously scored FFRangio measured index per vessel as compared with invasively-derived FFR; Index ≤ 0.80 is scored "positive" while Index \> 0.8 is negative.

Interventions

  • DEVICE FFRangio

Trial Details

FieldValue
Enrollment Target 382 participants
Start Date 2017-09-27
Est. Completion 2018-06-08
CathWorks

2 total trials

What the finished NCT03226262 record still lists

NCT03226262 is an observational study that tracks outcomes without assigning an intervention. The registered 382 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which FFRangio is the first listed.

NCT03226262 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03226262 about?

NCT03226262 is a clinical study titled "FFRangio Accuracy vs. Standard FFR". This is a prospective, observational, multi-center, single-arm, clinical trial designed to assess the efficacy of FFRangio in measuring FFR obtained from angiography compared to Invasive FFR for diagnosing hemodynamically significant coronary stenosis.

What is the current status of trial NCT03226262?

This trial is currently completed. The enrollment target is 382 participants. The study started on 2017-09-27. Estimated completion is 2018-06-08.

What interventions are being tested in trial NCT03226262?

The interventions under investigation include: FFRangio (DEVICE).

Who is sponsoring clinical trial NCT03226262?

This trial is sponsored by CathWorks, which has 2 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05677490 · 382 participants · Phase 3

    mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • NCT06196008 · 382 participants · NA

    Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers

  • NCT07100990 · 382 participants · Phase 3

    Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

  • NCT06056830 · 383 participants · Phase 3

    Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03226262, the US trial registry maintained by the National Library of Medicine. NCT03226262 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.